CJ-42794

Research use only, not for human use.

CJ-42794 is a selective antagonist of prostaglandin E receptor subtype 4 (EP4). It inhibits [3H]-PGE2 binding to the human EP4 receptor (a mean pKi: 8.5).

CJ-42794 is a selective antagonist of prostaglandin E receptor subtype 4 (EP4). It inhibits [3H]-PGE2 binding to the human EP4 receptor (a mean pKi: 8.5). CJ-42794 is a binding affinity that was at least 200-fold more selective for the human EP4 receptor than other human EP receptor subtypes (EP1, EP2, and EP3) (IC50 : 8.5 (pKi )).(In Vitro):EP4 in vitro: CJ-042794 competitively inhibits PGE2-evoked elevations of intracellular cAMP levels in HEK293 cells overexpressing human EP4receptor with a mean pA2 value of 8.6. CJ-042794 reverses the inhibitory effects of PGE2 on LPS-induced TNFα production in a concentration-dependent manner. (In Vivo):CJ-42794 significantly delays the ulcer healing in rats and mice and these responses were both attenuated by coadministration of CJ-42794.

CJ-042794

Others

Other Targets

human D2 receptor; human D3 receptor; human D4 receptor

——

——

847728-01-2

413.8

C22H17ClFNO4

>98% (HPLC)

——

C[C@H](NC(=O)c1cc(Cl)ccc1Oc1ccc(F)cc1)c1ccc(cc1)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years